Varex Imaging Corporation (Nasdaq: VREX) announced today that it is scheduled to present at CJS Securities 23rd Annual New Ideas for the New Year virtual investor conferences. Details are as follows:
CJS Securities 23rd Annual New Ideas for the New Year Conference
Varex will be presenting on Wednesday, January 11, 2023 at 3:45 PM ET.
The listen-only webcast link is: https://wsw.com/webcast/cjs5/vrex/1629129
The company’s Chief Financial Officer, Sam Maheshwari, will provide an overview of Varex’s business. Varex’s presentation will be webcast and accessible to the public via the company's website at vareximaging.com. Replays will be available for 90 days after the presentation at the same website.
About Varex
Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate Varex’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,300 people located in North America, Europe, and Asia. For more information visit vareximaging.com.
Last Trade: | US$7.32 |
Daily Change: | 0.16 2.23 |
Daily Volume: | 821,744 |
Market Cap: | US$301.800M |
February 03, 2025 December 23, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load